CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Precision Autoimmune Therapeutics Co., Ltd., (PAT), previously known as Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd (TIANSHI), has completed the first-round financing which raised RMB140 million (approximately $21 million). After completion of the first-round financing, CASI holds a 15% stake in PAT.
CASI Pharmaceuticals Announces Its Partner, Precision Autoimmune Therapeutics Co., Ltd Has Completed First-Round Financing of $21 Million
